Published in New England Journal of Medicine, 2021
In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis.
Recommended citation: The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. NEJM. Published online August 04, 2021. doi:10.1056/NEJMoa2103417 https://www.nejm.org/doi/full/10.1056/NEJMoa2103417